Daniel MacArthur at Genetic Future has a post about whether there will be value in sequencing the full genome of each newborn in the next decade. "There are plenty of very rare, severe disease mutations that would be clinically useful to detect at an early stage," he writes. "Secondly, pharmacogenomics is finally coming of age." He notes that advances from GWAS have begun to make the PGx field more viable, citing abacavir and statins as examples of drugs that can be kept away from patients who will have major adverse reactions "by typing a single genetic marker."
Welcome to Information Overload
Feb 16, 2009